Reviewer’s report

Title: Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype

Version: 3 Date: 8 September 2010

Reviewer: Hugo De Jonge

Reviewer’s report:

The author’s reply to comments 1-3 of my re-review is satisfactory. With respect to the author’s answer to comment 1, it should be noted that ex vivo studies of lubiprostone action in native mouse and human intestine, reporting a high potency of lubiprostone in inducing CFTR activation via EP4-cAMP-PKA signaling (EC50 of 50 nM; ref. 23), are clinically more relevant as compared to studies in the A6 Xenopus kidney cell line, which might lack one or more components of this signal transduction pathway, such as EP4 receptors.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.